Stock of the Day: Anthera Pharmaceuticals Inc Can’t Be More Safe. Trades Significantly Higher

Stock of the Day: Anthera Pharmaceuticals Inc Can't Be More Safe. Trades Significantly Higher

The stock of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is a huge mover today! About 238,718 shares traded hands. Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has declined 45.48% since April 4, 2016 and is downtrending. It has underperformed by 46.57% the S&P500.
The move comes after 9 months positive chart setup for the $94.87M company. It was reported on Nov, 4 by We have $5.82 PT which if reached, will make NASDAQ:ANTH worth $146.10M more.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Ratings Coverage

Out of 4 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Anthera Pharmaceuticals has been the topic of 7 analyst reports since August 13, 2015 according to StockzIntelligence Inc. As per Thursday, August 13, the company rating was upgraded by Zacks. The stock has “Buy” rating given by Suntrust Robinson on Wednesday, September 9. The stock has “Buy” rating given by Citigroup on Thursday, September 17. On Friday, July 8 the stock rating was initiated by H.C. Wainwright with “Buy”. The firm earned “Buy” rating on Friday, February 19 by Jefferies. The rating was initiated by SunTrust on Wednesday, September 9 with “Buy”.

According to Zacks Investment Research, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.”

Insitutional Activity: The institutional sentiment increased to 1.7 in Q2 2016. Its up 0.76, from 0.94 in 2016Q1. The ratio improved, as 6 funds sold all Anthera Pharmaceuticals Inc shares owned while 14 reduced positions. 5 funds bought stakes while 29 increased positions. They now own 22.69 million shares or 1.80% less from 23.11 million shares in 2016Q1.
Moreover, Millennium Mgmt has 0% invested in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 64,569 shares. Blackrock Institutional Trust Na holds 861,880 shares or 0% of its portfolio. Creative Planning has 2,000 shares for 0% of their US portfolio. Da Davidson And Company reported 61,950 shares or 0.01% of all its holdings. Goldman Sachs Grp Inc last reported 19,582 shares in the company. Jacobs Levy Equity Management owns 82,175 shares or 0.01% of their US portfolio. The Switzerland-based Credit Suisse Ag has invested 0% in Anthera Pharmaceuticals Inc (NASDAQ:ANTH). Nationwide Fund Advsrs, a Pennsylvania-based fund reported 25,816 shares. Moreover, New York State Common Retirement Fund has 0% invested in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 38,000 shares. Wexford Cap Lp has invested 0.08% of its portfolio in Anthera Pharmaceuticals Inc (NASDAQ:ANTH). Dimensional Fund Ltd Partnership last reported 28,760 shares in the company. Broadfin Cap Lc has 0.35% invested in the company for 1.15 million shares. Fincl Bank Of America De accumulated 0% or 26,569 shares. Proquest Associate Iv Ltd holds 2.39% of its portfolio in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 1.90 million shares. Franklin accumulated 0.01% or 3.20M shares.

More important recent Anthera Pharmaceuticals Inc (NASDAQ:ANTH) news were published by: which released: “BRIEF-Anthera Pharmaceuticals reports third quarter loss per shr of $0.61” on November 04, 2016, also published article titled: “Why Anthera Pharmaceuticals, Inc. Shares Are Soaring Higher”, published: “Anthera Pharma stock rises 7% on safety review board’s go-ahead for late-stage …” on August 16, 2016. More interesting news about Anthera Pharmaceuticals Inc (NASDAQ:ANTH) was released by: and their article: “Anthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public Offering” with publication date: July 09, 2015.

ANTH Company Profile

Anthera Pharmaceuticals, Inc. (Anthera), incorporated on October 9, 2004, is a biopharmaceutical firm focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment